WO2011047596A1 - Utilisation de composés d'hydroxybenzopyrone pour préparer un médicament utile pour la prévention et le traitement d'une fracture et de l'ostéoporose - Google Patents

Utilisation de composés d'hydroxybenzopyrone pour préparer un médicament utile pour la prévention et le traitement d'une fracture et de l'ostéoporose Download PDF

Info

Publication number
WO2011047596A1
WO2011047596A1 PCT/CN2010/077337 CN2010077337W WO2011047596A1 WO 2011047596 A1 WO2011047596 A1 WO 2011047596A1 CN 2010077337 W CN2010077337 W CN 2010077337W WO 2011047596 A1 WO2011047596 A1 WO 2011047596A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
formula
group
osteoporosis
compounds
Prior art date
Application number
PCT/CN2010/077337
Other languages
English (en)
Chinese (zh)
Inventor
李靖
孟坤
Original Assignee
北京盛诺基医药科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 北京盛诺基医药科技有限公司 filed Critical 北京盛诺基医药科技有限公司
Publication of WO2011047596A1 publication Critical patent/WO2011047596A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Definitions

  • This invention relates to the use of hydroxybenzopyrone compounds.
  • the compounds of the present invention are useful for preventing bone fractures, reducing the incidence of fractures, and promoting the repair of damaged bones after fractures, as well as preventing and treating osteoporosis.
  • the invention further relates to pharmaceutical compositions comprising these compounds, and to the use of said compounds, alone or in combination with other agents, to prevent fractures and to promote repair of damaged bones after fracture, and to prevent and treat osteoporosis.
  • Estrogen is a steroid hormone produced by the endocrine system in the body and plays an important role in the reproductive system, cardiovascular system, central nervous system, immune system and skeletal system. Recent studies have shown that estrogen exerts biological effects through two signaling pathways, the nuclear pathway and the cell membrane pathway; estrogen and its receptor signal transduction system are widely involved in cell growth, differentiation and apoptosis in multiple system tissues in vivo. . A large number of studies have confirmed the presence of estrogen receptors in the skeletal system, and their receptor expression levels are associated with skeletal development and osteoporosis; ER- ⁇ -mediated signal transduction pathways are likely to be involved in osteoporosis The formation and development process.
  • Estrogen has been used to treat osteoporosis for many years. Clinical observations have found that estrogen has a positive effect on reducing rapid bone loss after menopause, increasing bone mass, alleviating bone pain caused by osteoporosis, and reducing the incidence of fracture. Numerous studies have also confirmed that estrogen receptors are present in the skeletal system, and their receptor expression levels are associated with skeletal development and osteoporosis; estrogen receptor-mediated signal transduction pathways are involved in the formation of osteoporosis and development process. Selective estrogen receptor modulators developed for estrogen receptors, such as raloxifene, exhibit potent estrogen stimulatory effects on the skeletal system, increase bone density, and improve osteoporosis.
  • estrogen receptors are divided into two subtypes, alpha and beta; wherein ER-ct includes three homologs, ER-a66, ER-a46 and ER-a36.
  • the isoform ER-a36 is from the first ER-a66 gene
  • the promoter in the intron starts transcription and is encoded by ER- (a partial exon of x66. Therefore, ER-CL36 lacks two transcriptional functional regions, retaining the DNA-binding functional region and the dimerization functional region; It is important that the hormone ligand binding region of ER-a36 lacks a partial helix region, thus completely changing its specificity and affinity for binding to hormone ligands.
  • ER-CL36 is mainly distributed in cell membranes and cytoplasm, and is present in small amounts in In the nucleus, ER-CL36 regulates cell growth and apoptosis through the estrogen cell membrane signal transduction pathway (1. ZY,
  • the compounds of the present invention are useful as modulators of ER-ct and ER- ⁇ bioinformatics systems for the prevention and treatment of fractures and osteoporosis.
  • the present invention relates to a compound of formula (I), and a pharmaceutically acceptable salt or pharmaceutical composition thereof for the preparation of a prophylactic, therapeutic fracture and bone
  • RR 2 and R 3 are independently of each other selected from the group consisting of hydrogen, methyl, ethyl, propyl, and isopropyl.
  • the compound of formula (I) is a demethylated product of a compound of formula ( ⁇ ): 3,5,7-trihydroxy-2-(4-hydroxyphenyl 8-(3) -Methyl-2-butene-)-4H-benzopyran-4-one (aka: demethylated icariin),
  • the compound of the formula (I), and a pharmaceutically acceptable salt or pharmaceutical composition thereof, are prepared by the estrogen receptor ER- ⁇ and ER- ⁇ subtypes
  • R1, R2 and R3 are independently of each other selected from the group consisting of hydrogen, methyl, ethyl, propyl and isopropyl.
  • the compound of formula (I) is a demethylated product of a compound of formula ( ⁇ ): 3,5,7-trihydroxy-2-(4-hydroxyphenyl 8-(3) -Methyl-2-butene-)-4H-benzopyran-4-one (aka: demethylated icariin), that is, the compound of formula I) has the structure of formula ( ⁇ ):
  • the ER-ct subtypes include ER-a36, ER-a46 and ER-a66.
  • compound of formula (I) includes compounds of the formulae as defined herein, as well as all embodiments, preferred embodiments, more preferred embodiments and particularly preferred embodiments of the compounds, including the compounds disclosed in the specific names or examples, Each of these compounds is a particularly preferred embodiment of a compound defined by the formula.
  • compound of the present invention means any compound of the formula (I) as defined above.
  • treatment refers to the process of reversing, alleviating, inhibiting a disease or condition, or preventing such a disease or condition.
  • treatment refers to the act of treatment, The treatment therein is as defined above.
  • the invention further relates to a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of formula (I) and a pharmaceutically acceptable carrier.
  • the pharmaceutical composition may be administered orally in the form of a tablet, a capsule, a pill, a powder, a sustained release, a solution, or a suspension; the pharmaceutical composition may also be administered parenterally in the form of a sterile solution, suspension or emulsion.
  • the pharmaceutical composition may also be administered topically in the form of an ointment or cream; the pharmaceutical composition may also be administered rectally in the form of a suppository.
  • the pharmaceutical compositions may be presented in unit dosage form suitable for single administration of precise dosages.
  • the pharmaceutical composition includes a conventional pharmaceutical carrier or excipient and a compound of the present invention as an active ingredient.
  • the pharmaceutical composition may include other medical or pharmaceutical preparations, carriers, adjuvants. Suitable pharmaceutical carriers include inert diluents or fillers, water, and various organic solvents.
  • the pharmaceutical composition of the present invention may contain other ingredients such as a flavoring agent, a binder, an excipient, etc., if necessary.
  • the tablets may contain various excipients, for example citric acid and various disintegrating agents such as starch, alginic acid and certain complex silicates and binders such as sucrose, gelatin and arabic may be used. gum.
  • the tablets may also contain lubricants such as magnesium stearate, sodium lauryl sulfate and talc, which are often used in tablets.
  • a similar type of solid composition can also be used with soft and hard filled capsules.
  • Preferred materials include lactose or milk sugar and high molecular weight polyethylene glycol.
  • the aqueous suspension or elixirs can be combined with various sweetening or flavoring agents, pigments or dyes and, if desired, with emulsifiers or suspending agents, and diluents such as water, ethanol, Propylene glycol, glycerol or a combination thereof is administered in combination.
  • Exemplary parenteral administration forms include solutions or suspensions of the active compounds in sterile solutions, for example, propylene glycol or aqueous dextrose. Such dosage forms can be suitably buffered if desired.
  • the aqueous composition of the present invention may include other pharmaceutically acceptable solutes, including additives and other drugs, as the case may be. Suitable additives are those well known in the art including, but not limited to, antioxidants, antibacterials, surfactants, chelating agents, sugars, and preservatives.
  • the aqueous composition of the present invention can be administered by injection, wherein the injection can be intramuscular, intravenous or subcutaneous.
  • the compounds of the invention may be administered alone in terms of the intended route of administration and standard pharmaceutical practice, but are often administered with a suitable pharmaceutical excipient, diluent or carrier well known in the art. If appropriate, adjuvants may be added, including adjuvants, antioxidants, flavoring agents, or coloring agents.
  • suitable pharmaceutical compositions to provide direct, delayed, modified, sustained, pulsed or controlled release, depending on the particular route of administration and the specificity of the release profile, and Treatment needs to correspond.
  • oral refers to an oral administration method in which the oral use amount of the animal is expressly specified, for example, in a food or beverage, directly into the oral cavity, or freely selected.
  • animal refers to warm-blooded animals having adaptive functions in the animal kingdom, such as dogs and humans.
  • Typical oral solid forms can include tablets, powders, multiparticulate formulations (granules), capsules, chewables, lozenges, films, patches, and the like.
  • Typical oral liquid (including semi-solid and gelatinous) forms can include solutions, elixirs, gels, sprays, liquid-filled chews, and the like.
  • Other oral administration forms may also be employed in which the active agent is suspended in a liquid or semi-solid carrier phase, such as a suspension.
  • parenteral administration means that the route of administration does not pass through the mouth.
  • parenteral administration may include topical and transdermal, rectal, vaginal, nasal, inhalation and parenteral administration (requiring means of penetration through the skin barrier by needle and needle-free methods, including implants) And reservoir).
  • compositions of the invention include tablets.
  • the tablets are prepared by a process selected from the group consisting of direct compression or wet, dry or melt granulation, melt coagulation processes and extrusion.
  • the tablet core portion of the compositions of the present invention may be single or multi-layered, coated with a suitable coating material well known in the art.
  • the oral liquid form of the compound of the present invention is preferably a solution or suspension in which the active compound is sufficiently dissolved or partially dissolved.
  • the solution comprises the active compound and a pharmaceutically acceptable solvent suitable for oral administration.
  • the solvent is a solvent which exhibits good solubility for the compounds of the present invention. These solvents typically comprise a major portion of the formulation, i.e., greater than 50% by weight, preferably greater than 80%, such as 95%.
  • the solution further comprises an adjuvant or an additive.
  • the additive or adjuvant is a taste masking agent, a palatant, a flavoring agent, an antioxidant, a stabilizer, a texture modifier, a viscosity modifier, and a solubilizer.
  • Another embodiment is a process for the preparation of a preferred oral liquid form of a compound of the invention (see the pharmaceutical composition portion) wherein, in a suitable temperature range, each preferred component is optionally mechanically agitated or in a manner which facilitates dissolution rate Mix by ultrasonic agitation.
  • the preparation of the compound of the present invention is isolated and extracted from the raw material of the Chinese medicinal material.
  • Preparation of the compounds of the invention According to the method described in another invention patent "Preparation method of icariin" (Meng Kun, CN 101302548A), the chemical ingredient icariin is isolated and extracted from the Chinese medicinal material Epimedium, that is, the embodiment of the present invention 1 Compound (11).
  • the 24-week-old SD rats were treated with sham operation (Sham) or ovariectomy (OVX), and were randomly divided into groups of 8 animals each. Rats received different drug interventions. After 8 weeks, the uterus of each animal was collected and the uterine weight was weighed. The femurs of each animal were collected and the femur bone mineral density (Femur BMD) was measured. The expression of ER-CL36 receptor in rat endometrium was determined by immunohistochemistry. Western blot was used to detect ER-a66 and ER-a36 in rat endometrium and distal femoral cancellous bone. Receptor protein expression. DRAWINGS
  • Figure 1 Effect of compound ( ⁇ ) on femur bone density and uterine weight in rats.
  • A is a sham operation group
  • B is an oophorectomy group
  • C is an estradiol group
  • D is a raloxifene group
  • E is a compound ( ⁇ ) group.
  • Figure 4 Effect of compound ( ⁇ ) on the expression of ER-CL36 receptor protein in cancellous bone of distal femur.
  • This example compound was purchased from Shanghai Yousi Biotechnology Co., Ltd.
  • the present invention relates to a compound of formula (I), and a pharmaceutically acceptable salt or pharmaceutical composition thereof, for use in the prevention and treatment of fractures and osteoporosis.
  • the compound of the example ( ⁇ ) is now taken as an example and will be described in detail.
  • the ER-C136 receptor in estradiol rats The protein expression was less than that of the sham-operated group, and the expression of ER-CL36 receptor protein was significantly reduced in the raloxifene group and the compound ( ⁇ ) group (Fig. 4).

Landscapes

  • Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une utilisation d'un composé de formule (I), des sels pharmaceutiquement acceptables ou une composition pharmaceutique de celui-ci pour préparer un médicament pour la prévention et le traitement d'une fracture, de l'ostéoporose et des troubles régulés par des sous-types de récepteur d'hormone femelle de ER-α et ER-β.
PCT/CN2010/077337 2009-10-20 2010-09-26 Utilisation de composés d'hydroxybenzopyrone pour préparer un médicament utile pour la prévention et le traitement d'une fracture et de l'ostéoporose WO2011047596A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2009101808819A CN102038674A (zh) 2009-10-20 2009-10-20 羟基苯并吡喃酮类化合物在制备预防和治疗骨折和骨质疏松药物中的应用
CN200910180881.9 2009-10-20

Publications (1)

Publication Number Publication Date
WO2011047596A1 true WO2011047596A1 (fr) 2011-04-28

Family

ID=43899819

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2010/077337 WO2011047596A1 (fr) 2009-10-20 2010-09-26 Utilisation de composés d'hydroxybenzopyrone pour préparer un médicament utile pour la prévention et le traitement d'une fracture et de l'ostéoporose

Country Status (2)

Country Link
CN (1) CN102038674A (fr)
WO (1) WO2011047596A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102600126B (zh) * 2012-03-19 2013-09-11 昆明理工大学 异戊烯基黄酮化合物的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1460482A (zh) * 2003-06-08 2003-12-10 浙江大学 一种含淫羊藿素、去甲基淫羊藿素的药物组合物及其用途
CN101528038A (zh) * 2006-10-25 2009-09-09 盛诺基医药科技有限公司 用于治疗与雌激素受体相关的疾病的化合物和方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1460482A (zh) * 2003-06-08 2003-12-10 浙江大学 一种含淫羊藿素、去甲基淫羊藿素的药物组合物及其用途
CN101528038A (zh) * 2006-10-25 2009-09-09 盛诺基医药科技有限公司 用于治疗与雌激素受体相关的疾病的化合物和方法

Also Published As

Publication number Publication date
CN102038674A (zh) 2011-05-04

Similar Documents

Publication Publication Date Title
US8252835B2 (en) Compounds and methods for treating estrogen receptor-related diseases
CA2376158C (fr) Utilisation de modulateurs selectifs des recepteurs des oestrogenes dans la fabrication de medicaments visant a traiter et/ou a prevenir la prise ponderale
AU2002243411B2 (en) Combination of an estrogen and an androgen for treating hormonal deficiencies in women undergoing estrogen replacement therapy
CN108289960B (zh) Ep4受体拮抗剂用于治疗nash相关肝癌的用途
CN101641013A (zh) 核受体结合剂
HU230162B1 (hu) Fulvesztrantot tartalmazó gyógyászati készítmény
CN102018698A (zh) 治疗雌激素受体相关疾病的化合物及其方法
EP1450813B1 (fr) Antagonistes de recepteurs de prostaglandine ep2 et/ou ep4 pour le traitement de la menorragie
WO2011047595A1 (fr) Utilisation de composés d'hydroxybenzopyrone dans la préparation d'un médicament utile pour traiter la leucémie
JP2001500101A (ja) 乳癌の治療及び予防のための医薬組成物の製造のためのセントクロマンのｌ―鏡像異性体の使用
WO2003099292A1 (fr) Traitement des symptomes post-menopausiques chez des patientes atteintes du cancer du sein, ce traitement comprenant la tibolone et un oestrogene de confection
WO2011047596A1 (fr) Utilisation de composés d'hydroxybenzopyrone pour préparer un médicament utile pour la prévention et le traitement d'une fracture et de l'ostéoporose
WO2014063660A1 (fr) Polythérapie de naringénine et d'acide asiatique pour le traitement d'une fibrose
JP2001504804A (ja) Ｆａｓ発現阻害方法
JP4166433B2 (ja) ホルモン依存性疾患治療剤
CA2956514A1 (fr) Traitement des symptomes associes a une therapie par deprivation androgenique
JPH03294230A (ja) 子宮内膜症治療剤
EP4129283A1 (fr) Association pharmaceutique et son utilisation
AU2006291059A1 (en) Salicylate and gentisate salts of a piperazine compound
US10272124B2 (en) Use of helminthostachys, ugonins or flavone-based compounds for the treatment or prevention of metabolic diseases
WO2011047597A1 (fr) Composés de dihydroxybenzopyranone, compositions médicales de ceux-ci, et leur utilisation pour traiter et prévenir une fracture et l'ostéoporose
KR20040018335A (ko) 성 기능 장애의 예방 및 치료에 유용한 약제의 제조에서ｎ-아세틸-ｄ-글루코사민의 용도
JP2001048805A (ja) 骨粗鬆症、心臓血管疾患および胸部ガンを治療し予防する治療薬
CN116077515A (zh) 重楼皂苷1作为雌激素拮抗剂的应用
TW200902028A (en) Combination of progesterone-receptor antagonist together with an aromatase inhibitor for use in BRCA mediated diseases

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10824437

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10824437

Country of ref document: EP

Kind code of ref document: A1